UniQure's FDA Shift Shows Biotech Value Depends On The Gatekeeper
UniQure's plan to seek FDA approval for a Huntington's disease gene therapy shows how regulatory posture can rapidly change biotech financing, deal value, and risk.
2026-06-21 · 4 min read